The impact of perampanel on cognition: A systematic review of studies employing standardized tests in patients with epilepsy.


Journal

Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 30 09 2021
revised: 01 12 2021
accepted: 02 12 2021
pubmed: 11 12 2021
medline: 30 12 2021
entrez: 10 12 2021
Statut: ppublish

Résumé

This systematic review was conducted to reveal the cognitive effects of perampanel (PER) as assessed by objective standardized neuropsychological measures in patients with epilepsy. A systematic literature search was performed in PubMed. In addition we cross-checked a list of relevant studies (based on a ProQuest search) provided by Eisai GmbH. Eligibility criteria were (1) group studies reporting the cognitive outcome of treatment with PER in patients with epilepsy (2) which employed objective cognitive tests and (3) were published in English. Of the 56 initially retrieved records, 9 eligible studies were included in the qualitative synthesis. Two studies were based on the very same sample. Altogether the included studies analyzed a total of 241 patients (46% pediatric) with adjunctive PER. All studies were longitudinal with assessments before and after introduction of PER (up to 5 follow-ups and observation intervals of up to 1 year). Two studies were retrospective, 6 lacked a control condition. Neuropsychological assessments varied in extent and test selection. Overall no systematic cognitive deteriorations or improvements after introduction of PER have been reported across the analyzed studies. The only randomized placebo-controlled trial found a transient worsening in attention and speed of memory at the 19-week follow-up, and in addition a late decline in another parameter of attention at the final 52-week follow-up. This systematic review on the objective cognitive effects of PER suggests an overall neutral cognitive profile of PER with no systematic cognitive deteriorations or improvements. More controlled studies on the cognitive effects of PER would be appreciated.

Identifiants

pubmed: 34890976
pii: S1059-1311(21)00388-5
doi: 10.1016/j.seizure.2021.12.001
pii:
doi:

Substances chimiques

Anticonvulsants 0
Nitriles 0
Pyridones 0
perampanel H821664NPK

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-111

Informations de copyright

Copyright © 2021 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Auteurs

Juri-Alexander Witt (JA)

Department of Epileptology, University Hospital Bonn (UKB), Bonn, Germany. Electronic address: juri-alexander.witt@ukbonn.de.

Christoph Helmstaedter (C)

Department of Epileptology, University Hospital Bonn (UKB), Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH